Plain-English translation of NCT05183854 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether giving two pneumococcal vaccines—PCV20 and PPSV23—in a series can help people with chronic lymphocytic leukemia develop better protection against pneumococcal disease (a serious bacterial infection). People with CLL often have weakened immune systems, so the study wants to see if this vaccine combination helps their bodies fight off this infection more effectively.
People with chronic lymphocytic leukemia have weakened immune systems and are at higher risk of getting serious pneumococcal infections. Researchers want to find out whether giving these two vaccines together can help protect patients better than vaccination alone might in healthier people.
You likely qualify if…
You likely don't qualify if…
You will receive two vaccine injections over about 75 days. The first vaccine (PCV20) will be given at your first visit, and the second vaccine (PPSV23) will be given at a follow-up visit approximately 10 weeks later. Researchers will monitor your immune response to see how well your body responds to these vaccines over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States